Timeline
More in Healthcare
SkinBioTherapeutics restates FY25 after £0.77m fabricated royalty, HY26 revenue up 37%
SkinBioTherapeutics has restated audited FY25 revenue to £3.87m from £4.64m after an independent investigation found £0.77m of accrued royalty revenue was inappropriately recognised and fabricated by the former CEO.